NASDAQ
Innate Pharma S.A. (IPHYF) has a price/sales ratio of 58.73x as of Friday, May 22, 2026. This represents a 356.05% increase compared to its 12-month average of 12.88x. The price-to-sales ratio evaluates a company's stock price relative to its revenue, useful for valuing companies with little or no earnings.
No price data available for this timeframe.